News
The day at a glance · 3 min read
Mood · Risk-On
+75
Sentiment, −100 to +100
LLY Market Cap
$1 trillion
LLY Share Price
$1,000+
Viking Upside Target
160%
Key driverEli Lilly's historic $1 trillion valuation milestone and multiple FDA approvals across big pharma and medical devices drive sector optimism
Daily briefHealthcare· Money365.Market AI ·

Lilly Hits $1 Trillion; AbbVie, Abbott Win FDA Nods

Eli Lilly becomes first pharma to reach $1 trillion valuation as shares top $1,000; AbbVie gains rare cancer approval, Abbott secures AI imaging clearance

Big Pharma & Biotech

Bullish
LLYABBV
Eli Lilly ($LLY) has reached a historic milestone, becoming the first pharmaceutical company to achieve a $1 trillion market valuation as shares surged above $1,000. The company's robust performance has been driven by its obesity drug franchise, with analysts upgrading $LLY to Strong Buy despite higher costs from acquisitions and underwhelming performance from Foundayo. The GLP-1 rally that propelled $LLY higher in May also benefited competitors, though Truist highlighted Viking Therapeutics as a differentiated player with its VK2735 candidate and dual oral-plus-injectable GLP-1 strategy, assigning a 160% upside target.
AbbVie ($ABBV) secured FDA approval for DECNUPAZ (pivekimab sunirine-pvzy), a targeted therapy for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer with limited treatment options. The approval was supported by data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of the therapy.

MedTech & Devices

Bullish

ABT Stock Price

$85.68-1.14%

TMO Growth Target

7%
ABTISRGTMO
Abbott Laboratories ($ABT) received FDA and EU regulatory clearance for its Ultreon 3.0 software, an AI-powered coronary imaging platform designed to guide artery stent placement. Despite this positive regulatory development, $ABT shares declined 1.14% to close at $85.68. The medical device sector saw significant innovation announcements across multiple platforms this week.
Intuitive Surgical ($ISRG) announced that more than 100 improvements will roll out to U.S. customers of its da Vinci 5 robotic surgical system starting in June, including extended instrument use capabilities. Meanwhile, Thermo Fisher Scientific ($TMO) outlined its long-term strategic priorities at its annual Investor Day, setting a bold 7% annual growth target as the company focuses on strengthening its position in life sciences tools and diagnostics.

Health Insurance & Managed Care

Neutral
UNH
UnitedHealth Group ($UNH) is pursuing digital transformation initiatives across its insurance and Optum health services divisions, according to a new enterprise technology ecosystem analysis. The company's main market opportunities lie in expanding health insurance services across diverse segments while leveraging Optum's comprehensive platform for innovation, product launches, and strategic acquisitions. Notably, Berkshire Hathaway under Greg Abel's leadership has exited its $UNH position, though the timing of the sale came before the stock's recent rally.

Looking Ahead

Neutral

U.S. Market (1 Week)

+2.5%

U.S. Market (1 Year)

+26%

Earnings Growth Proj.

17%
JNJREGN
Johnson & Johnson ($JNJ) will host its second-quarter earnings conference call on July 15th, providing investors with insights into the company's pharmaceutical, medical device, and consumer health performance. The broader healthcare sector continues to show strength, with U.S. markets up 2.5% over the past week and 26% over the past year, while earnings are projected to grow by 17% annually. Competition in the eczema treatment market intensified as Apogee Therapeutics revealed mixed results for its experimental therapy aimed at rivaling Regeneron's Dupixent, underscoring the ongoing innovation race in immunology.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy